Literature DB >> 15662814

Long-term results of Leksell gamma knife surgery for trigeminal schwannomas.

Li Pan1, En-Min Wang, Nan Zhang, Liang-Fu Zhou, Bing-Jiang Wang, Ya-Fei Dong, Jia-Zhong Dai, Pei-Wu Cai.   

Abstract

OBJECT: The authors evaluated the long-term efficacy of gamma knife surgery (GKS) in patients with trigeminal schwannomas.
METHODS: Fifty-six patients, 31 women and 25 men (mean age 42 years), underwent GKS for trigeminal schwannomas. Fourteen had previously undergone surgery, and GKS was the primary treatment in the remaining 42 patients. The mean target volume was 8.7 cm3 (range 0.8-33 cm3); the mean maximum dose was 27 Gy (range 20-40 Gy); the mean tumor margin dose was 13.3 Gy (range 10-15 Gy); and the mean follow-up period was 68 months (range 27-114 months). Disappearance of the tumor occurred in seven patients. An obvious decrease in tumor volume was observed in 41 patients, four tumors remained unchanged, and four tumors progressed at 5, 26, 30, and 60 months, respectively. One patient with disease progression died of tumor progression at 36 months after GKS. The tumor growth control rate in this group was 93% (52 of 56 cases). Mild numbness or diplopia was relieved completely in 14 patients. Improvement of other neurological deficits was demonstrated in 25 patients. Trigeminal nerve dysfunction was either unchanged or slightly worse in 13 patients after GKS. Four patients experienced mild symptom deterioration related to tumor progression.
CONCLUSIONS: Radiosurgery proved to be an effective treatment for small- and medium-sized trigeminal schwannomas. Some larger tumors are also suitable for radiosurgery if there is no significant brainstem compression.

Entities:  

Mesh:

Year:  2005        PMID: 15662814     DOI: 10.3171/jns.2005.102.s_supplement.0220

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  8 in total

1.  Trigeminal schwannomas: experience with 57 cases and a review of the literature.

Authors:  Raita Fukaya; Kazunari Yoshida; Takayuki Ohira; Takeshi Kawase
Journal:  Neurosurg Rev       Date:  2010-10-21       Impact factor: 3.042

2.  Clinical and Imaging Response to Trigeminal Schwannoma Radiosurgery: A Retrospective Analysis of a 28-Year Experience.

Authors:  Ajay Niranjan; Sudesh S Raju; Hideyuki Kano; John C Flickinger; Lawrence Dade Lunsford
Journal:  J Neurol Surg B Skull Base       Date:  2020-08-14

3.  Multimodality Management of Trigeminal Schwannomas.

Authors:  Ajay Niranjan; Samuel Barnett; Vijay Anand; Siviero Agazzi
Journal:  J Neurol Surg B Skull Base       Date:  2016-04-22

4.  Trigeminal neurinomas: clinical features and surgical experience in 84 patients.

Authors:  Xiao-Dong Liu; Qi-Wu Xu; Xiao-Ming Che; De-Ling Yang
Journal:  Neurosurg Rev       Date:  2009-07-25       Impact factor: 3.042

5.  Gamma knife radiosurgery for trigeminal schwannoma: a 20-year experience with long-term treatment outcome.

Authors:  Jiwook Ryu; Sung Ho Lee; Seok Keun Choi; Young Jin Lim
Journal:  J Neurooncol       Date:  2018-06-21       Impact factor: 4.130

Review 6.  Trends in the Management of Non-Vestibular Skull Base and Intracranial Schwannomas.

Authors:  Carlos Suárez; Fernando López; William M Mendenhall; Simon Andreasen; Lauge Hjorth Mikkelsen; Johannes A Langendijk; Stefano Bondi; Juan P Rodrigo; Leif Bäck; Antti A Mäkitie; Verónica Fernández-Alvarez; Andrés Coca-Pelaz; Robert Smee; Alessandra Rinaldo; Alfio Ferlito
Journal:  Cancer Manag Res       Date:  2021-01-18       Impact factor: 3.989

7.  A case of malignant peripheral nerve sheath tumor of the hypoglossal nerve after stereotactic radiosurgery treatment.

Authors:  Tong Yang; Gordana Juric-Sekhar; Donald Born; Laligam N Sekhar
Journal:  J Neurol Surg Rep       Date:  2014-05-02

Review 8.  Tumor control and trigeminal dysfunction improvement after stereotactic radiosurgery for trigeminal schwannomas: a systematic review and meta-analysis.

Authors:  Iulia Peciu-Florianu; Jean Régis; Marc Levivier; Michaela Dedeciusova; Nicolas Reyns; Constantin Tuleasca
Journal:  Neurosurg Rev       Date:  2020-11-13       Impact factor: 3.042

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.